A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review

被引:10
|
作者
Zaman, Chowdhury F. [1 ]
Sultana, Jakia [2 ]
Dey, Proma [3 ]
Dutta, Jui [2 ]
Mustarin, Sadia [4 ]
Tamanna, Nuzhat [5 ]
Roy, Aditi [6 ]
Bhowmick, Nisha [7 ]
Khanam, Mousumi [8 ]
Sultana, Sadia [9 ]
Chowdhury, Selia [8 ]
Khanam, Farjana [10 ]
Sakibuzzaman, Md [11 ,12 ,13 ,14 ]
Dutta, Priyata [15 ]
机构
[1] Jahurul Islam Med Coll & Hosp, Med & Surg, Kishoreganj, Bangladesh
[2] Cumilla Med Coll, Med, Cumilla, Bangladesh
[3] Chittagong Med Coll, Internal Med, Chattogram, Bangladesh
[4] Mymensingh Med Coll, Med, Mymensingh, Bangladesh
[5] Rangpur Med Coll & Hosp, Med, Rangpur, Bangladesh
[6] Sher E Bangla Med Coll, Med, Barisal, Bangladesh
[7] Shaheed Ziaur Rahman Med Coll, Med, Bogra, Bangladesh
[8] Dhaka Med Coll, Internal Med, Dhaka, Bangladesh
[9] Anwer Khan Modern Med Coll, Med, Dhaka, Bangladesh
[10] Cent Med Coll, Med, Cumilla, Bangladesh
[11] Univ Toledo, Neurol, 2801 W Bancroft St, Toledo, OH 43606 USA
[12] Univ Mississippi, Med Ctr, Internal Med, Jackson, MS 39216 USA
[13] Sir Salimullah Med Coll, Internal Med, Dhaka, Bangladesh
[14] Mayo Clin, Expt Pathol Canc Biol, Rochester, MN USA
[15] St Joseph Mercy Ann Arbor, Internal Med, Trinity Hlth, Ann Arbor, MI USA
关键词
nafld; nonalcoholic fatty liver disease; covid-19; gut microbiota; hepatocellular carcinoma (hcc); metabolic syndrome; obesity; nonalcoholic fatty liver disease (nafld); HEPATOCELLULAR-CARCINOMA; MEDITERRANEAN DIET; PATHOGENESIS; PREVENTION; MANAGEMENT; FUTURE;
D O I
10.7759/cureus.29657
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent times, nonalcoholic fatty liver disease (NAFLD) has been considered one of the major causes of liver disease across the world. NAFLD is defined as the deposition of triglycerides in the liver and is associated with obesity and metabolic syndrome. Hyperinsulinemia, insulin resistance (IR), fatty liver, hepatocyte injury, unbalanced proinflammatory cytokines, mitochondrial dysfunction, oxidative stress, liver inflammation, and fibrosis are the main pathogenesis in NAFLD. Recent studies suggest that the action of intestinal microbiota through chronic inflammation, increased intestinal permeability, and energy uptake plays a vital role in NAFLD. Moreover, polycystic ovarian syndrome also causes NAFLD development through IR. Age, gender, race, ethnicity, sleep, diet, sedentary lifestyle, and genetic and epigenetic pathways are some contributing factors of NAFLD that can exacerbate the risk of liver cirrhosis and hepatocellular carcinoma (HCC) and eventually lead to death. NAFLD has various presentations, including fatigue, unexplained weight loss, bloating, upper abdominal pain, decreased appetite, headache, anxiety, poor sleep, increased thirst, palpitation, and a feeling of warmth. Some studies have shown that NAFLD with severe coronavirus disease 2019 (COVID-19) has poor outcomes. The gold standard for NAFLD diagnosis is liver biopsy. Other diagnostic tools are imaging tests, serum biomarkers, microbiota markers, and tests for extrahepatic complications. There are no specific treatments for NAFLD. Therefore, the main concern for NAFLD is treating the comorbid conditions such as anti-diabetic agents for type 2 diabetes mellitus, statins to reduce HCC progression, antioxidants to prevent hepatocellular damage, and bariatric surgery for patients with a BMI of >40 kg/m(2) and >35 kg/m(2) with comorbidities. Lifestyle and dietary changes are considered preventive strategies against NAFLD advancement. Inadequate treatment of NAFLD further leads to cardiac consequences, sleep apnea, chronic kidney disease, and inflammatory bowel disease. In this systematic review, we have briefly discussed the risk factors, pathogenesis, clinical features, and numerous consequences of NAFLD. We have also reviewed various guidelines for NAFLD diagnosis along with existing therapeutic strategies for the management and prevention of the disease.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Current strategies for nonalcoholic fatty liver disease treatment (Review)
    Sun, Jing
    Jin, Xiuli
    Li, Yiling
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2024, 54 (04)
  • [2] Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective
    Samji, Naga S.
    Verma, Rajanshu
    Satapathy, Sanjaya K.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (04) : 497 - 505
  • [3] Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach
    Alisi, Anna
    Feldstein, Ariel E.
    Villani, Alberto
    Raponi, Massimiliano
    Nobili, Valerio
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (03) : 152 - 161
  • [4] Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea
    Im, Hwi Jin
    Ahn, Yo Chan
    Wang, Jing-Hua
    Lee, Myung Min
    Son, Chang Gue
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (04)
  • [5] An update on nonalcoholic fatty liver disease
    Provencher, Daniel M.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2014, 27 (07): : 18 - 22
  • [6] Nonalcoholic fatty liver disease from a primary care perspective
    Clark, Jeanne M.
    Cryer, Donna R. H.
    Morton, Michelle
    Shubrook, Jay H.
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1421 - 1433
  • [7] Nonalcoholic Fatty Liver Disease A Systematic Review
    Rinella, Mary E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (22): : 2263 - 2273
  • [8] Nonalcoholic fatty liver disease: A clinical approach and review
    Raman, Maitreyi
    Allard, Johane
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 20 (05) : 345 - 349
  • [9] Nonalcoholic Fatty Liver Disease: Current Concepts
    Tziomalos, Konstantinos
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (38) : 4564 - 4565
  • [10] Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
    Blazina, Ian
    Selph, Shelley
    SYSTEMATIC REVIEWS, 2019, 8 (01)